Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Innate and adaptive immunity for the pathobiology of Parkinson's disease.

Stone DK, Reynolds AD, Mosley RL, Gendelman HE.

Antioxid Redox Signal. 2009 Sep;11(9):2151-66. doi: 10.1089/ARS.2009.2460. Review.

2.
3.

Ethyl pyruvate rescues nigrostriatal dopaminergic neurons by regulating glial activation in a mouse model of Parkinson's disease.

Huh SH, Chung YC, Piao Y, Jin MY, Son HJ, Yoon NS, Hong JY, Pak YK, Kim YS, Hong JK, Hwang O, Jin BK.

J Immunol. 2011 Jul 15;187(2):960-9. doi: 10.4049/jimmunol.1100009. Epub 2011 Jun 17.

4.

A possible role for humoral immunity in the pathogenesis of Parkinson's disease.

Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM.

Brain. 2005 Nov;128(Pt 11):2665-74. Epub 2005 Oct 11.

PMID:
16219675
5.

Increased mitochondrial calcium sensitivity and abnormal expression of innate immunity genes precede dopaminergic defects in Pink1-deficient mice.

Akundi RS, Huang Z, Eason J, Pandya JD, Zhi L, Cass WA, Sullivan PG, Büeler H.

PLoS One. 2011 Jan 13;6(1):e16038. doi: 10.1371/journal.pone.0016038.

6.

Immunological features of alpha-synuclein in Parkinson's disease.

Roodveldt C, Christodoulou J, Dobson CM.

J Cell Mol Med. 2008 Oct;12(5B):1820-9. doi: 10.1111/j.1582-4934.2008.00450.x. Epub 2008 Jul 30. Review. Erratum in: J Cell Mol Med. 2008 Dec;12(6B):2875.

7.

Pathogenesis of nigral cell death in Parkinson's disease.

Przedborski S.

Parkinsonism Relat Disord. 2005 Jun;11 Suppl 1:S3-7. Review.

PMID:
15885625
8.

Inflammatory response in Parkinson's disease (Review).

Yan J, Fu Q, Cheng L, Zhai M, Wu W, Huang L, Du G.

Mol Med Rep. 2014 Nov;10(5):2223-33. doi: 10.3892/mmr.2014.2563. Epub 2014 Sep 12. Review.

PMID:
25215472
9.

Novel role of aquaporin-4 in CD4+ CD25+ T regulatory cell development and severity of Parkinson's disease.

Chi Y, Fan Y, He L, Liu W, Wen X, Zhou S, Wang X, Zhang C, Kong H, Sonoda L, Tripathi P, Li CJ, Yu MS, Su C, Hu G.

Aging Cell. 2011 Jun;10(3):368-82. doi: 10.1111/j.1474-9726.2011.00677.x. Epub 2011 Mar 22.

10.

Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

L'Episcopo F, Tirolo C, Caniglia S, Testa N, Serra PA, Impagnatiello F, Morale MC, Marchetti B.

J Neuroinflammation. 2010 Nov 23;7:83. doi: 10.1186/1742-2094-7-83.

11.

Modulation of control mechanisms of dopamine-induced apoptosis--a future approach to the treatment of Parkinson's disease?

Ziv I, Offen D, Barzilai A, Haviv R, Stein R, Zilkha-Falb R, Shirvan A, Melamed E.

J Neural Transm Suppl. 1997;49:195-202. Review.

PMID:
9266428
12.

Glial reactions in Parkinson's disease.

McGeer PL, McGeer EG.

Mov Disord. 2008 Mar 15;23(4):474-83. Review.

PMID:
18044695
13.

Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention.

Tansey MG, Goldberg MS.

Neurobiol Dis. 2010 Mar;37(3):510-8. doi: 10.1016/j.nbd.2009.11.004. Epub 2009 Nov 10. Review.

14.

CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson's disease.

Pabon MM, Bachstetter AD, Hudson CE, Gemma C, Bickford PC.

J Neuroinflammation. 2011 Jan 25;8:9. doi: 10.1186/1742-2094-8-9.

15.

Nigrostriatal neuronal death in Parkinson's disease--a passive or an active genetically-controlled process?

Ziv I, Barzilai A, Offen D, Nardi N, Melamed E.

J Neural Transm Suppl. 1997;49:69-76. Review.

PMID:
9266415
16.

Iron as a vulnerability factor in nigrostriatal degeneration in aging and Parkinson's disease.

Floor E.

Cell Mol Biol (Noisy-le-grand). 2000 Jun;46(4):709-20. Review.

PMID:
10875434
17.

Monitoring therapeutic effects in Parkinson's disease by serial imaging of the nigrostriatal dopaminergic pathway.

Booij J, Berendse HW.

J Neurol Sci. 2011 Nov 15;310(1-2):40-3. doi: 10.1016/j.jns.2011.07.029. Epub 2011 Aug 15. Review.

PMID:
21840542
18.

Neuroinflammation in Parkinson's disease.

Lee JK, Tran T, Tansey MG.

J Neuroimmune Pharmacol. 2009 Dec;4(4):419-29. doi: 10.1007/s11481-009-9176-0. Epub 2009 Oct 10. Review.

19.

Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein.

Watson MB, Richter F, Lee SK, Gabby L, Wu J, Masliah E, Effros RB, Chesselet MF.

Exp Neurol. 2012 Oct;237(2):318-34. doi: 10.1016/j.expneurol.2012.06.025. Epub 2012 Jun 27.

20.

Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system.

Hunter RL, Dragicevic N, Seifert K, Choi DY, Liu M, Kim HC, Cass WA, Sullivan PG, Bing G.

J Neurochem. 2007 Mar;100(5):1375-86. Epub 2007 Jan 23.

Supplemental Content

Support Center